Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death

被引:61
作者
Olsen, C. Holkmann
Mocroft, A.
Kirk, O.
Vella, S.
Blaxhult, A.
Clumeck, N.
Fisher, M.
Katlama, C.
Phillips, A. N.
Lundgren, J. D.
机构
[1] Copenhagen HIV Programme, Hvidovre, Denmark
[2] UCL Royal Free & Univ Coll Med Sch, Royal Free Ctr HIV Med, London, England
[3] UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London, England
[4] Ist Super Sanita, I-00161 Rome, Italy
[5] Karolinska Univ Sjukhuset, Infekt Kliniken, Solna, Sweden
[6] CHU St Pierre, Brussels, Belgium
[7] Brighton Gen Hosp, Brighton, E Sussex, England
[8] Hop La Pitie Salpetriere, Paris, France
关键词
D O I
10.1111/j.1468-1293.2007.00436.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives The aim of the study was to compare incidence rates (IRs) of AIDS/death in patients with and without treatment interruption (TI) of combination antiretroviral therapy (cART) for periods of 3 months or more for different categories of CD4 cell count and viral load, and to determine risk factors for clinical progression to AIDS/death. Methods Patients starting cART with a CD4 cell count and a viral load available within 6 months of starting cART were included in the study. The IR and risk factors of TI were determined. We assessed the incidence rate ratios (IRRs) for TI and AIDS/death events using Poisson regression models. Results Of 3811 patients included in the study, 26% were ART-naive prior to cART. The median date of starting cART was July 1997, the median CD4 cell count was 226 cells/mu L and the median viral load was 4.36 log(10) HIV-1 RNA copies/mL. We observed 1243 interruptions and 403 AIDS-events/deaths. The IR of AIDS/death was higher in patients with lower CD4 cell counts or higher viral loads, regardless of TI. After adjusting for baseline factors, the IR of AIDS/death was significantly higher in the TI group than in the non-TI group [IRR 2.63; 95% confidence interval (CI) 2.01-3.44; P < 0.0001]; this could be explained by current CD4 cell counts and viral loads, as the CD4 cell count- and viral load-adjusted IRR was 1.14 (95% CI 0.86-1.51; P=0.37). Within the TI group, patients with a current CD4 cell count of < 200 cells/mu L had a 3-fold higher risk of AIDS/death than those with a CD4 cell count of 200-350 cells/mu L, whereas patients with a current CD4 cell count of > 350 cells/mu L had a 4-fold lower risk of disease progression. Conclusions TI is common in clinical practice. The risk of AIDS/death increased more than 2-fold for patients stopping all cART regimen drugs for 3 months or more. Among patients experiencing a TI, those with low CD4 cell counts, high viral loads or prior AIDS had an increased risk of AIDS/death. Hence, TI should be discouraged and closely monitored if it occurs.
引用
收藏
页码:96 / 104
页数:9
相关论文
共 36 条
[1]  
Ananworanich J, 2005, ANTIVIR THER, V10, P761
[2]  
[Anonymous], 1992, MMWR Recomm Rep, V41, P1
[3]   First-line therapy and mitochondrial damage:: Different nucleosides, different findings [J].
Blanco, F ;
García-Benayas, T ;
de la Cruz, JJ ;
González-Lahoz, J ;
Soriano, V .
HIV CLINICAL TRIALS, 2003, 4 (01) :11-19
[4]   HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management [J].
Carr, A .
AIDS, 2003, 17 :S141-S148
[5]   Adverse effects of antiretroviral therapy [J].
Carr, A ;
Cooper, DA .
LANCET, 2000, 356 (9239) :1423-1430
[6]  
DARMINIO MA, 2005, J ACQ IMMUN DEF SYND, V38, P407
[7]   Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response [J].
Deeks, SG ;
Grant, RM ;
Wrin, T ;
Paxinos, EE ;
Liegler, T ;
Hoh, R ;
Martin, JN ;
Petropoulos, CJ .
AIDS, 2003, 17 (03) :361-370
[8]   Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens [J].
Dorrucci, M ;
Pezzotti, P ;
Grisorio, B ;
Minardi, C ;
Muro, MS ;
Vullo, V ;
Monforte, AD .
AIDS, 2001, 15 (13) :1733-1736
[9]  
El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360
[10]   Combination antiretroviral therapy and the risk of myocardial infarction [J].
Friis-Moller, N ;
Sabin, CA ;
Weber, R ;
Monforte, AD ;
El-Sadr, WM ;
Reiss, P ;
Thiébaut, R ;
Morfeldt, L ;
De Wit, S ;
Pradier, C ;
Calvo, G ;
Law, MG ;
Kirk, O ;
Phillips, AN ;
Lundgren, JD ;
Lundgren, JD ;
Weber, R ;
Monteforte, AD ;
Bartsch, G ;
Reiss, P ;
Dabis, F ;
Morfeldt, L ;
De Wit, S ;
Pradier, C ;
Calvo, G ;
Law, MG ;
Kirk, O ;
Phillips, AN ;
Houyez, F ;
Loeliger, E ;
Tressler, R ;
Weller, I ;
Friis-Moller, N ;
Sabin, CA ;
Sjol, A ;
Lundgren, JD ;
Sawitz, A ;
Rickenbach, M ;
Pezzotti, P ;
Krum, E ;
Meester, R ;
Lavignolle, V ;
Sundström, A ;
Poll, B ;
Fontas, E ;
Torres, F ;
Petoumenos, K ;
Kjær, J ;
Hammer, S ;
Neaton, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :1993-2003